Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
They will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.
Pharmaceutical industry investors are betting on contract development and manufacturing organizations (CDMOs) this year, as they shift their focus from contract research organizations (CRO).
J&J said the acquisition will allow its subsidiary, Janssen Pharmaceutical, to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease.
Under terms of the deal, Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion.
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering Thursday.
Pfenex’ proprietary protein production platform, Pfenex Expression Technology, is used to improve existing treatments and create novel therapies.
With a $425 million upfront payment, Bayer bolstered its women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and its investigational treatment for menopause.
AlloVir raised $276 million in an upsized initial public offering. The funds will be used to advance the company’s efforts to develop an allogeneic cell therapy to control infections in immunocompromised patients.
Cerevel Therapeutics, which spun out of Pfizer two years ago, entered into a business combination deal with Arya Sciences Acquisition Corp II, a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors.
COVID-19 put many businesses on hold, but not biotech. This sector is growing at record speeds, and only a small portion of the capital deals are related to the pandemic.